<DOC>
	<DOCNO>NCT00193323</DOCNO>
	<brief_summary>In randomized trial , attempt define optimal palliative chemotherapy elderly patient advance non-small cell lung cancer compare single agent treatment weekly docetaxel versus combination therapy weekly docetaxel plus gemcitabine .</brief_summary>
	<brief_title>Weekly Docetaxel Versus Weekly Docetaxel/Gemcitabine Treatment Non-Small Cell Lung Cancer Elderly Patients</brief_title>
	<detailed_description>Upon determination eligibility , patient randomly assign one two treatment arm : Docetaxel Docetaxel + Gemcitabine For ever 2 patient treat , 1 receive treatment A ( docetaxel ) 1 receive treatment B ( Docetaxel + Gemcitabine ) . The study blind patient doctor know treatment assign .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>To include study , must meet following criterion : Biopsyproven nonsmall cell lung cancer No previous chemotherapy . Age &gt; 65 year Age &lt; 65 year require significant assistance perform activity daily Stage IV disease stage IIIB disease Ability perform activity daily live minimal assistance Measurable evaluable disease Adequate bone marrow , liver kidney All patient must sign write informed consent prior study entry . You participate study follow apply : Brain metastasis Meningeal metastases Other uncontrolled malignancy History invasive cancer last 5 year Moderate severe peripheral neuropathy Please note : There additional inclusion/exclusion criterion . The study center determine meet criterion . If qualify trial , study personnel explain reason . If qualify , study personnel explain trial detail answer question may .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
</DOC>